ISEV2019 Abstract Book
Total Page:16
File Type:pdf, Size:1020Kb
Journal of Extracellular Vesicles ISSN: (Print) 2001-3078 (Online) Journal homepage: https://www.tandfonline.com/loi/zjev20 ISEV2019 Abstract Book To cite this article: (2019) ISEV2019 Abstract Book, Journal of Extracellular Vesicles, 8:sup1, 1593587, DOI: 10.1080/20013078.2019.1593587 To link to this article: https://doi.org/10.1080/20013078.2019.1593587 © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles. Published online: 23 Apr 2019. Submit your article to this journal Article views: 1036 View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=zjev20 JOURNAL OF EXTRACELLULAR VESICLES 2019, VOL. 8, 1593587 https://doi.org/10.1080/20013078.2019.1593587 ISEV2019 Abstract Book About ISEV The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes. With nearly 1000 members, ISEV continues to be the leader in advancing the study of extracellular vesicles. Founded in 2012 in Sweden, ISEV has since moved its headquarters to the USA. Through its programmes and services, ISEV provides essential training and research opportunities for those involved in exosome and microvesicle research. Mission statement Advancing extracellular vesicle research globally. Vision Our vision is to be the leading advocate and guide of extracellular vesicle research and to advance the under- standing of extracellular vesicle biology. ISEV2019 Annual Meeting The International Society for Extracellular Vesicles is the premier international conference of extracellular vesicle research, covering the latest in exosomes, microvesicles and more. With an anticipated 1000 attendees, ISEV2019 will feature presentations from the top researchers in the field, as well as providing opportunities for talks from students and early career researchers. ISEV2019 International Organizing Committee IOC Chair: Hidetoshi Tahara, Ph.D. (Japan); Andrew Hill, Ph.D. (Australia), Carolina Soekmadji, Ph.D. (Australia), Cherie Blenkiron, Ph.D. (New Zealand), Edit Buzas, Ph.D. (Hungary), Hang Hubert Yin, Ph.D. (China), Juan Falcon Perez, Ph.D. (Spain), Kazunari Akiyoshi, Ph.D. (Japan), Kenneth W. Witwer, Ph.D. (USA), Kyoko Hida, Ph.D. (Japan), Lei Zheng (China), Marca Wauben, Ph.D. (The Netherlands), Mariko Ikuo, Ph.D. (Japan), Masahiko Kuroda, M.D., Ph.D. (Japan), Nobuyoshi Kosaka, Ph.D. (Japan), Ryou-u Takahashi, Ph.D. (Japan), Sai-Kiang Lim, Ph.D. (Singapore), Susmita Sahoo, Ph.D. (USA), Takahiro Ochiya, Ph.D. (Japan), Tang- Long Shen, Ph.D. (Taiwan), Yong Song Gho, Ph.D. (Korea) and Yoshinobu Takakura, Ph.D. (Japan) Journal of extracellular vesicles: Editors-in-Chief Clotilde Thery, Ph.D. (France) © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. 2 ISEV2019 ABSTRACT BOOK JOURNAL OF EXTRACELLULAR VESICLES 3 Plenary Session 1: Standardizations Chairs: Andrew Hill; Hidetoshi Tahara Location: Level 3, Hall B NanoCosmos: extracellular vesicles as nanosized extracellular extracellular vesicles derived from host, bacteria, diet organelles delivering the complex messages between cells and and environments including their physical, biochem- organisms Yong Song Gho ical and biological complex properties (http://evpedia. Department of Life Sciences, POSTECH, Pohang, Republic of Korea info). Then, this presentation focuses on our recent progress in novel extracellular vesicle-mimetic technol- The secretion of nanosized lipid bilayered extracellular ogies for targeted drug delivery, theranostics and epi- vesicles is a universal cellular process occurring from genetic reprogramming as well as for adjuvant-free, simple organisms to complex multicellular organisms. non-toxic vaccine delivery system against bacterial Recent progress in this area has revealed that extracel- infection. Furthermore, bacterial extracellular vesicle- lular vesicles play multifaceted pathophysiological based cancer immunotherapy will be introduced. Based functions by delivering the complex messages between on the concept of emergent properties of heteroge- cells and organisms, suggesting that extracellular vesi- neous extracellular vesicles, future research directions cles are NanoCosmos, i.e., extracellular organelles that to decode the complexity of extracellular vesicle- play diverse roles in intercellular and interkingdom mediated intercellular communication network, either communication. This presentation briefly introduces at the single vesicle level or at a systems level as a our last 20 year’s comprehensive research on whole, and the secret of life will be briefly introduced. 4 ISEV2019 ABSTRACT BOOK Symposium Session 1: Cardiovascular Disease Thursday 25 April 2019 Chairs: J. Brian Byrd; Pia Siljander Location: Level B1, Hall B 11:00–12:30 OT01.01 otherwise wild-type, naïve mice mobilize splenic neutro- phils to peripheral blood (P <0.001). Summary/Conclusion: Neutrophils appear at sites of Extracellular vesicles mediate neutrophil cell deployment from the injury in the immediate hours after ischemic injury. spleen following acute myocardial infarction Neutrophil interactions with EC-EV may mediate their Naveed Akbar and Robin Choudhury splenic liberation and transcriptional programming fol- University of Oxford, Oxford, UK lowing AMI, en route to the injured myocardium. The Introduction: Acute myocardial infarction (AMI) mobi- splenic neutrophil reserve may be a novel therapeutic lizes monocytes from the splenic reserve and induces target in AMI. transcriptional activation en route to the injured myo- Funding: British Heart Foundation. cardium, possibly through interactions involving plasma liberated extracellular vesicles (EVs). Neutrophils also OT01.02 reside in the spleen and are the first cells to arrive at sites of injury and mediate further damage. Here, we describe neutrophil deployment from the spleen in AMI In vivo characterization of endogenous cardiovascular extracellular vesicles and their response to ischaemic injury and by endothelial cell (EC)-derived EVs. Aaron Scotta, Costanza Emanuelib and Rebecca Richardsonc Methods: Patients provided informed consent as part of aUniversity of Bristol, Uffculme, UK; bImperial College London, London, UK; the Oxford Acute Myocardial Infarction Study. EV were cUniversity of Bristol, Bristol, UK isolated using ultra centrifugation (120,000g 2h)and characterized for size and concentration by Nanoparticle Introduction: Cardiomyocytes and endothelial cells are Tracking Analysis, EV markers (TSG101, ALIX, CD63/ counted among the cell types that secrete extracellular CD69) by western blot, and microRNAs (miRNAs) by vesicles (EVs). EVs mediate the targeted transfer of RT-qPCR. Mouse and human EC were used in vitro to lipids, proteins and nucleic acids by traversing the derive EC-EV. extracellular milieu. Recent studies suggest that EVs Results:PatientspresentingwithAMI(n =15)have2.2- play a functional role in cardiovascular disease and fold more plasma EV at time of injury vs. a 6-month cardiac repair. For example, a population of exosomes follow-up measurement (P =0.008).PlasmaEVsatthe carrying proangiogenic miRNAs was found in the peri- time of presentation correlate significantly with the extent cardial fluid of patients undergoing heart surgery. of ischemic injury (R =0.046,P =0.006)andplasma Further investigation will be required to determine neutrophils (R =0.37,P =0.017).ExperimentalAMIin which cardiac cells are producing these EVs, the cell wild type, naïve (C57B6/J) mice induces splenic-neutro- type receiving them and the functional relevance of phil deployment (P =0.004).HumanplasmaEV- this. miRNAs are significantly altered post-AMI. AMI plasma Methods: A complete understanding of this process EV-miRNA-mRNA targets (IPA, Qiagen) are signifi- requires a comprehensive in vivo model. The zebrafish cantly over represented when compared to neutrophil is an amenable vertebrate model with genetic tractabil- Gene Ontology terms for degranulation (P <0.001),acti- ity and optical transparency allowing for subcellular vation (P <0.001),chemotaxis(P =0.008)andmigration observation in a living organism. The use of stable (P =0.008).HumanECreleasesmoreEVafterinflam- transgenic lines with cell-type-specific promoters driv- matory stimulation (control 2.4 ×108 ± 4.9 x 107 EVs/ ing the expression of membrane tethered fluorophores mL vs. tumour necrosis factor-alpha stimulated, allows labelling of the cell membrane and the EVs 1.4 ×109 ± 3.0 ×108 EVs/mL, P = 0.003) and contains produced by individual cell types. Light sheet micro- many of the miRNAs enriched in human plasma-EV scopy permits cardiovascular-specific EVs to be tracked following AMI. Mouse EC-EV tail vein injected into in vivo and an established ischaemic injury model JOURNAL OF EXTRACELLULAR VESICLES 5 allows EV profiles from uninjured, injured and repair- assessed by flow cytometry (Reddel et al. Thromb ing/regenerating cardiac tissue to be determined and Haemost. 2018; 118(4): 723–733) using fluorescent